ASCO 2023 Bladder Cancer

Viewing 1-20 of 29 articles

ASCO 2023: Discussant: THOR – Results of Erdafitinib versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations

ASCO 2023: Phase 3 THOR Study: Results of Erdafitinib Versus Chemotherapy in Patients with Advanced or Metastatic Urothelial Cancer with Select Fibroblast Growth Factor Receptor Alterations

ASCO 2023: Final Analysis Results from a Multicenter Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin as Neoadjuvant Therapy in Patients with cT2-T4aN0M0 MIBC

ASCO 2023: Efficacy of Sacituzumab Govitecan in Locally Advanced or Metastatic Urothelial Cancer by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

ASCO 2023: Activity of Cabozantinib plus Durvalumab in Patients with Advanced Urothelial Carcinoma or Non-UC Variant Histologies After Platinum Chemotherapy: Interim Results from the Phase 2 ARCADIA Trial

ASCO 2023: Independent Biomarkers Predictive of Outcomes with Enfortumab Vedotin in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study

ASCO 2023: Biomarkers of Response to Sacituzumab Govitecan and Efficacy After Treatment with Enfortumab Vedotin in Advanced Urothelial Carcinoma: Analysis of the UNITE Study

ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data

ASCO 2023: Discussant: Advanced Urothelial Carcinoma: Striking a Balance of Efficacy and Safety

ASCO 2023: Discussant: The Power of Patients' Experiences to Inform Therapeutic Decisions

ASCO 2023: Long-Term Safety of Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial

ASCO 2023: Safety Analysis by UGT1A1 Status of TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Cancer Who Progressed After Platinum -Based Chemotherapy and a Checkpoint Inhibitor

ASCO 2023: FGFR3 Alterations in PROOF 302: A Phase III Trial of Infigratinib (BGJ398) as Adjuvant Therapy in Patients with Invasive Urothelial Carcinoma

ASCO 2023: Discussant: Optimizing Outcomes in Upfront Management of Localized Bladder Cancer

ASCO 2023: Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder

ASCO 2023: ADVANCED-2: Phase 1b/2 Dose Expansion, Open-Label Study to Evaluate Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade NMIBC

ASCO 2023: Long-Term Outcomes of Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial

ASCO 2023: Tumor Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study

ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data

ASCO 2023: Biology and Performance of Pre- and Post-Pembrolizumab VI-RADS to Predict the Pathological Response in MIBC: Full Data Analysis from a Clinical Trials Pipeline

1
2